Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).
暂无分享，去创建一个
L. Sehn | F. Bosch | I. Flinn | N. Bartlett | M. Wei | Sung-Soo Yoon | W. Kim | A. Kwan | S. Schuster | M. Shadman | M. Matasar | C. Diefenbach | B. Bender | L. Nastoupil | S. Assouline | J. Hong | L. Budde | K. Yousefi | S. Yin | Wang Cunlin